ArticleCancer medicine2026
Validation of the 9th Edition of the Tumor-Node-Metastasis Staging System for Non-Metastatic Nasopharyngeal Carcinoma: A Multicenter Retrospective Analysis From High-Incidence Regions.
Article in Cancer medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
objectiveTo evaluate and compare the prognostic value of the 8th and 9th editions of the American Joint Committee on Cancer (AJCC)/Union for International Cancer Control (UICC) staging system in patients with non-metastatic nasopharyngeal carcinoma (NPC).
methodsClinical data from 470 patients with NPC treated between November 2019 and June 2022 were retrospectively analyzed. Patients were restaged according to the 8th and 9th editions of the AJCC/UICC staging system. OS was the primary endpoint; locoregional recurrence-free survival (LRFS), distant metastasis-free survival (DMFS), and disease-free survival (DFS) were secondary endpoints. Kaplan-Meier curves were compared using global and pairwise log-rank tests. Prognostic discriminative ability was evaluated using the concordance index (C-index) and Akaike information criterion (AIC).
resultsSeventeen patients (3.6%) classified as T3 by TNM-8 were reclassified as T4 by TNM-9. Thirty-one patients (6.6%) were reclassified to N3 because of advanced iENE. TNM-9 improved discrimination for DMFS across N categories (log-rank p < 0.001 vs. p = 0.016 for TNM-8) and for OS (p < 0.001 vs. p = 0.042). T categories discriminated LRFS in both editions (p = 0.012 for each), whereas OS differences were not significant (TNM-8 p = 0.139; TNM-9 p = 0.137). TNM-9 overall stage discriminated OS (p = 0.002), unlike TNM-8 (p = 0.121). Both editions discriminated DFS (both p < 0.001), but TNM-9 provided better pairwise separation between early and advanced overall stages. The 9th edition exhibited enhanced predictive performance compared with the 8th edition, as evidenced by higher C-index values and lower Akaike information criterion (AIC) values for both DFS and OS prediction across overall stages.
conclusionThe 9th edition of the AJCC/UICC staging system demonstrated superior prognostic discriminative ability compared with the 8th edition, enabling more accurate risk stratification and supporting more informed clinical decision-making for patients with NPC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.